Clinical analysis of chemo-resistance risk factors in endometriosis associated ovarian cancer

Tong Ren, Tingting Sun, Ting-Ting Sun, Shu Wang, Jian Sun, Yang Xiang, Keng Shen, Jinghe Lang, Jing-He Lang
Journal of ovarian research · 2018 · vol. 11(1) , pp. 40 · doi:10.1186/s13048-018-0418-8 · PMID:29843765 · W2806887105
article OA: gold CC0 ⤵ 2 in-corpus citations
📄 Open PDF View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This study identified advanced FIGO stage, lack of lymphadenectomy, positive lymph nodes, and a history of breast cancer as independent risk factors for platinum-based drug resistance in endometriosis-associated ovarian cancer.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-10 ⓘ

This retrospective clinical analysis reviewed 304 patients with endometriosis-associated ovarian cancer, including ovarian clear cell carcinoma and endometrioid carcinoma, who received initial treatment at one hospital over 12 years, to identify factors linked to platinum-based chemotherapy resistance. Platinum-based drug resistance occurred in 17.1%, and univariate analyses associated resistance with older age, abdominal distension/emaciation symptoms, abnormal preoperative CA125 patterns, advanced FIGO stage, high-grade tumors, absence of endometriosis, bilateral tumors, inadequate lymphadenectomy, positive lymph nodes, residual disease >1 cm, and history of breast cancer; however, multivariate analysis found only advanced FIGO stage, lack of lymphadenectomy, positive lymph nodes, and breast cancer history as independent risk factors (P < 0.05). The authors did not identify several other candidate factors (including onset age, symptoms, CA125 level, coexisting endometriosis, and residual tumors) as independent in multivariable modeling. This paper is centrally about endometriosis-associated ovarian cancer — it analyzes clinical risk factors for platinum-based chemoresistance specifically in endometriosis-associated ovarian clear cell and endometrioid carcinomas.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

BACKGROUND: To analyze the clinical characteristics and chemo-resistance related factors of patients with resistant and non-resistant endometriosis-associated ovarian cancer (ovarian clear cell carcinoma and endometrioid carcinoma) by reviewing the data of epithelial ovarian cancer patients who received initial treatment in our hospital over a 12-year period. RESULTS: Among the 304 patients, 17.1% were seen with platinum-based drug resistance. The ROC curve of continuous variables was drawn according to resistance situation, then they were grouped by age (< 48 or ≥ 48 years), tumor size (< 7 cm or ≥ 7 cm) and Ca125 (< 90 and ≥ 90 U/ml). In univariate analysis, age ≥ 48 years, initial symptom of abdominal distension or weight loss, abnormal preoperative serum Ca125, Ca125 < 90 U/ml, advanced FIGO stage, absence of endometriosis, bilateral tumors, lack of lymphadenectomy, positive lymph nodes, unsatisfactory initial cytoreduction surgery and history of breast cancer were all related to drug resistance in ovarian cancer. In multivariate analysis, advanced stage, lack of lymphadenectomy, positive lymph nodes and history of breast cancer were independent risk factors related to platinum-based drug resistance (P < 0.05). CONCLUSION: For patients of endometriosis-related ovarian cancer, platinum-based drug resistance were associated with advanced FIGO stage, lack of lymphadenectomy, positive lymph nodes and history of breast cancer.

My notes (saved in your browser only)

Condition tags

mesh:D004715endometriosis

MeSH descriptors

CA-125 Antigen Endometriosis Membrane Proteins Ovarian Neoplasms Adult Aged Breast Neoplasms Breast Neoplasms Breast Neoplasms CA-125 Antigen Cytoreduction Surgical Procedures Cytoreduction Surgical Procedures Drug Resistance, Neoplasm Drug Resistance, Neoplasm Endometriosis Endometriosis Endometriosis Endometriosis Female Humans

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (2)

References (22)

Cited by (2)

SciLite annotations

chemicals 26
platinum platinum platinum platinum platinum platinum platinum platinum platinum platinum platinum paclitaxel carboplatin platinum platinum platinum platinum platinum cisplatin cisplatin cisplatin hydroxyl 2-chloro-2'-deoxyadenosine-5'-triphosphate platinum platinum platinum

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:19:49.066213+00:00
scilite
last seen: 2026-05-18T04:25:29.313245+00:00
License: CC0 · commercial use OK